Edges in Network
| Network | GSE25065_egf1520 - GSE25065 - SiGN-BN HC+Bootstrap |
| Network Description | Validation cohort for genomic predictor of response and survival following neoadjuvant taxane-anthracycline chemotherapy in breast cancer |
| Node | SLC16A6 |
| Upstream (Parents) |
|---|
| (<<) CHST3 → SLC16A6 |
| (<<) CRYAB → SLC16A6 |
| (<<) EGFR → SLC16A6 |
| (<<) EPN3 → SLC16A6 |
| (<<) ERBB3 → SLC16A6 |
| (<<) GDF15 → SLC16A6 |
| (<<) GPX7 → SLC16A6 |
| (<<) HSPB1 → SLC16A6 |
| (<<) IGFBP4 → SLC16A6 |
| (<<) MLPH → SLC16A6 |
| (<<) MMP7 → SLC16A6 |
| (<<) MREG → SLC16A6 |
| (<<) NRIP1 → SLC16A6 |
| (<<) PHGDH → SLC16A6 |
| (<<) PRKAB1 → SLC16A6 |
| (<<) PTK7 → SLC16A6 |
| (<<) SLPI → SLC16A6 |
| (<<) SPDEF → SLC16A6 |
| (<<) SPR → SLC16A6 |
| (<<) TFF1 → SLC16A6 |
| (<<) UBE2E3 → SLC16A6 |
| Downstream (Children) |
|---|
| SLC16A6 → ADCY9 (>>) |
| SLC16A6 → ADORA2B (>>) |
| SLC16A6 → ANTXR1 (>>) |
| SLC16A6 → ARHGEF4 (>>) |
| SLC16A6 → ATF4 (>>) |
| SLC16A6 → CALML5 (>>) |
| SLC16A6 → CCND1 (>>) |
| SLC16A6 → CDC42EP1 (>>) |
| SLC16A6 → DUSP5 (>>) |
| SLC16A6 → ENO2 (>>) |
| SLC16A6 → EPHB3 (>>) |
| SLC16A6 → FDPS (>>) |
| SLC16A6 → FOSL1 (>>) |
| SLC16A6 → GNAI1 (>>) |
| SLC16A6 → IER3 (>>) |
| SLC16A6 → ITGA6 (>>) |
| SLC16A6 → KCNN4 (>>) |
| SLC16A6 → KHDRBS3 (>>) |
| SLC16A6 → KLK10 (>>) |
| SLC16A6 → MAP3K12 (>>) |
| SLC16A6 → NPAS3 (>>) |
| SLC16A6 → PLA2R1 (>>) |
| SLC16A6 → PODXL (>>) |
| SLC16A6 → PRKX (>>) |
| SLC16A6 → PSAT1 (>>) |
| SLC16A6 → RBKS (>>) |
| SLC16A6 → RBP1 (>>) |
| SLC16A6 → SIGLEC15 (>>) |
| SLC16A6 → SLC6A14 (>>) |
| SLC16A6 → SMAD5 (>>) |
| SLC16A6 → TNFRSF11A (>>) |
| SLC16A6 → TPM4 (>>) |
| SLC16A6 → TSG101 (>>) |
| SLC16A6 → TSPO (>>) |
| SLC16A6 → TYRO3 (>>) |
| SLC16A6 → UBE2D2 (>>) |
| SLC16A6 → UGDH (>>) |
| SLC16A6 → WWTR1 (>>) |
